CD22 is another target explored in the treatment of B-cell lymphomas and leukemias in several ongoing clinical studies (i.e., NCT03999697, NCT04546906, NCT04088890). This evidence concerns the gene CD22 and B-cell non-Hodgkin lymphoma.